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Summary Fifty patients affected by histologically confirmed gastrointestinal tract cancer (GTC) were treated
with oral tegafur (TG) 1,000-mg m-2 p.o. on days 1-14 repeated after a 14 day interval. Out of 42 evaluable
patients seven patients had a partial response (PR, 17%) with a median duration of 20.5 weeks, three had a
minimal response (7%) with a median duration of 23.7 weeks, nine showed a stabilisation which lasted a
median of 31.3 weeks, and 23 progressed (55%). No response was obtained in patients affected by carcinoma
of the pancreas and the hepatobiliary system. All PRs were achieved in patients with metastatic disease to the
liver. No response was seen in patients with bone, lung or nodal metastasis. Three PRs were obtained in
patients resistant to 5-fluorouracil. The difference in survival between patients who achieved PR and those who
had a stabilisatiot was not statistically significant. On the other hand the survival of patients with PR was
significantly longer than that of patients who progressed. Oral TG was well tolerated by most patients. WHO
grade 1-2 gastrointestinal and neurological toxicities were seen respectively in 36% and 25% of cases. Five
patients had grade 3 nausea/vomiting and one had grade 3 diarrhoea. Our data suggest that oral TG is
effective in the treatment of stomach and colorectal cancers.
The fluoropyrimidines are among the most active classes of
anti-neoplastic agents employed in the treament of gastro-
intestinal tract cancers (GTC). 5-Fluorouracil (5-FU), which
is the most widely used fluoropyrimidine anti-metabolite, has
been shown to yield a 15-30% overall response rate in
advanced and/or metastatic gastrointestinal carcinomas
(Carter, 1976; Comis & Carter, 1974; Carter & Comis, 1976).
Although 5-FU is rather active in these tumours, repeated
administration of 5-FU is often associated with a significant
and sometime severe gastrointestinal and haematological tox-
icity (Friedman & Ignoffo, 1980). Tegafur (TG), a
tetradhydro-2-furanyl derivative of 5-fluorouracil, has been
reported to be effective by the intravenous route against
GTC yielding an 11-25% overall response rate (Blokhina et
al., 1972; Buroker et al., 1977; Schutt et al., 1983). TG,
administered intravenously, causes a significant and dose-
related neurological toxicity in 15-70% of patients due to its
ability to cross easily the blood-brain barrier (Friedman &
Ignoffo, 1980; Bedikian et al., 1983). Butyrolactone, a
metabolite produced during TG activation, is thought to be
partly responsible for neurotoxicity (Au & Sadee, 1980).
Neurological side-effects have been the dose-limiting toxicity
in about one-third of patients receiving intravenous TG
(Carter & Slavik, 1976; Friedman & Ignoffo, 1980). TG is
also well absorbed after oral administration, and it has been
reported to yield a 20% overall response rate in GTC. It is
also less toxic than 5-FU and TG given intravenously
(Bedikian et al., 1983). TG is considered to be a pro-drug of
5-FU and it exerts its activity, at least in part, after conver-
sion to 5-FU (Benvenuto et al., 1978; Diasio et al., 1979; Van
Putten et al., 1979). After oral administration of TG, the
plasma concentration of 5-FU and the cumulative areas
under the concentration versus time curve have been reported
to be comparable to those obtained after a 5-day continuous
infusion of 5-FU (Schilcher et al., 1983). However, other
authors reported that following TG administration, serum
5-FU levels have been found to be extremely low (often
undetectable), suggesting that TG is converted intracellularly
to 5-FU which may not be redistributed into the circulation
before further metabolisation (Au & Sadee, 1979; Au et al.,
1979; Hornbeck et al., 1981). Oral TG, at the dose of
1,000-1,500 mg m2 day-', causes moderate neurological
and gastrointestinal toxicity in about 10-20% of patients,
thus showing that the oral route is more suitable for clinical
purposes than the intravenous administration (Dindogru et
al., 1980; Hunter & Browder, 1980).
In this paper we report the results of a phase II study
carried out to evaluate and confirm the range of activity and
the toxicity of tegafur given orally as single agent in the
palliative treatment of advanced and/or metastatic GTC.
Patients and methods
Fifty patients affected by locally advanced or metastatic
gastrointestinal tract cancer were included in this study after
oral informed consent. Accrual criteria were: age <75 years;
performance status (Karnofsky index, KI) >50; histo-
logically confirmed GTC; life expectancy >2 months;
measurable disease; 4 week interval since last treatment;
adequate marrow (WBC > 4,000 mm-3, PLT >
120,000 mm-3, Hb > 10 g%), liver (serum bilirubin
<1.2 mg%), and renal (BUN <50 mg%, serum creatinine
< 1.2 mg%) functions; no major metabolic, neurological or
cardiac disease.
The main clinical characteristics of patients are shown in
Table I. There were 31 males (62%) and 19 females (38%)
with a mean age of 62 years (range 38-75). Mean perfor-
mance status according to Karnofsky score was 74 (range
50-90). Thirteen patients (26%) had gastric carcinoma, three
(6%) hepatocarcinoma, four (8%) gall bladder cancer, five
(10%) pancreatic carcinoma and the remaining 25 (50%)
patients were affected by colorectal carcinoma. Thirty-six
patients (72%) had received surgery as primary treatment,
while 14 (28%) had inoperable primary disease. Sixteen out
of42 patients (32%) were pretreated with chemotherapy: two
patients had received adriamycin for their hepatocarcinoma,
one patient 5-fluorouracil (5-FU) for rectal carcinoma, one
mitomycin C (MMC) plus BCNU and 5-FU for rectal car-
cinoma, one cisplatinum (CDDP) for advanced gastric
cancer, and 11 patients had received FAM chemotherapy
(5-FU, ADM, MMC) for advanced gastric carcinoma.
Pretreatment evaluation included: complete history,
physical examination, standard X-ray of the thorax, sono-
gram of the abdomen, haematological parameters, blood
chemistry tests, CEA, TPA, Ca 19-9. CT scan, endoscopy
and bone survey were employed as needed.
The treatment plan was: ftorafur 1000mg m2 p.o. on
days 1- 14 repeated after a 14 day interval or when recovery
from toxicity was obtained. The World Health Organization
(WHO) criteria have been employed for definition of clinical
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Table I Characteristics of patients
No. enrolled patients
Age
mean
range
Sex
male
female
Performance status
(Karnofsky index)
mean
range
Previous treatments
surgery
chemotherapy
radiotherapy
Sites of primary
stomach
hepatocarcinoma
gall bladder
pancreas
colo-rectal
Sites of disease
inoperable primary
locoregional recurrency
metastatic disease
liver
lung
bone
node
50
62
38-75
31 (62%)
19 (38%)
74
50-90
36 (72%)
16 (32%)
2 (4%)
13 (26%)
3 (6%)
4 (8%)
5 (10%)
25 (50%)
14 (28%)
6 (12%)
40 (80%)
33
3
7
objective response and toxicity. CT scan was employed to
confirm the regression of liver metastasis and the absence of
otherwise undetectable tumoral deposit in the abdomen.
Patients were considered evaluable after completion of at
least two courses of oral ftorafur. Serum chemistries and
haematological tests were performed before, during and after
each course to monitor toxicity. Student's t test was em-
ployed for statistical analysis and the Kaplan-Meier method
for actuarial survival curve.
Results
Forty-two out of 50 enrolled patients were evaluable for
response, while three patients were lost to follow-up, two
patients died before completion of two cycles, and one
patient refused therapy. Two further patients were not con-
sidered evaluable because of low compliance. Type and dura-
tion of objective response are shown in Table II. Out of 42
evaluable, six patients (17%) showed a partial response (PR)
with a median duration of 20.5 weeks (range 13.3-28.6) and
three (7%) had a minor response (MR) with a median dura-
tion of 23.7 weeks (range 18.1-29.4). Nine patients (21%)
showed a stabilisation of their disease (no change, NC),
which lasted a median of 31.3 weeks (range 16.0-61.4), while
23 patients (55%) unfortunately progressed. All PRs were
obtained in patients with hepatic metastasis, while no re-
sponse was seen in cases with bone, lung and nodal secon-
dary neoplastic lesions. Patients with an objective response
reported an mean increase of their performance status of
20% (Karnofsky score).
Table II Type and duration of response
Duration of Survival
Type of response (weeks) (weeks)
response No. median (range) median (range)
PR 7 (17%) 20.5 (13.3-28.6) 26.8 (18.7-95.0)
MR 3 (7%) 23.7 (18.1-29.4) 53.5 (28.1-79.0)
NC 9 (21%) 31.3 (16.0-61.4) 65.2 (22.4-82.0)
PD 23 (55%) 10.8 ( 3.0-43.1)
No. of patients evaluable for response = 42. PR, partial response;
MR, minimal response; NC, stabilisation of disease; PD, progressive
disease.
Table III depicts objective responses according to the type
of primary cancer. No response or stabilisation were
obtained in pancreatic carcinoma (n = 5), gall bladder car-
cinoma (n = 3) and epatocarcinoma (n = 3), while four PR
(33%) were obtained in gastric carcinoma (n = 12). Out of
18 patients with colorectal carcinoma three (17%) achieved
PR, two patients (11%) MR, six NC (33%) and seven
patients (39%) progressed. Out of 10 patients previously
treated with 5-FU containing regimens, three patients (30%)
achieved an objective response (PR), three (30%) did not
progress (NC) and four (40%) showed no response.
The impact of tegafur therapy on survival is shown in
Table II and Figure 1. Patients who had PR (median survival
26.8 weeks) did not survive longer than patients who had a
stabilisation of their disease (median 53.5 weeks). The
difference in median survival between patients who re-
sponded (PR + MR) and those who progressed (median sur-
vival 10.8 weeks) is statistically significant (P <0.001).
Out of 50 enrolled patients, 44 (88%) were evaluable for
toxicity. Toxic effects of oral TG according to WHO criteria
are shown in Table IV. During a total of 161 complete cycles
administered, the most frequent side-effects were: grade 1-3
nausea/vomiting in 48% of patients (only one case of grade
3), and grade 1-2 neurological toxicity in 25% of cases,
mainly in the form of dizziness, headache, insomnia and
lethargy. Neurological toxicity was generally mild and in no
case was it dose-limiting. No renal and cardiac toxicities were
seen.
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Figure I Survival of patients treated with oral TG according to
objective response. Patients who had a partial response (median
survival 26.8 weeks) did not survive longer than patients who had
a stabilisation of disease (median survival 53.3 weeks). The
difference in median survival between patients who responded
and those who progressed (median survival 10.8 weeks) is statis-
tically significant (P <0.001).
Table III Response according to primary neoplasm
No. of Type of response
Type patients PR MR NC PD
Stomach 12 4 (33%) 1 (8%) 3 (25%) 4 (33%)
Pancreas 5 0 0 0 5 (100%)
Liver 3 0 0 0 3 (100%)
Gall bladder 4 0 0 0 4 (100%)
Colorectal 18 3 (17%) 2 (11%) 6 (33%) 7 (39%)
Total 42 7 (17%) 3 (7%) 9 (21%) 23 (55%)ORAL TEGAFUR AND GI TRACT CANCERS 477
Table IV Toxicity from oral tegafur
No. evaluable patients 44 (100%)
No. of patients without any toxicity 13 (29%)
Gastrointestinal
nausea/vomiting 21 (48%)
grade 1-2 16 (36%)
grade 3 5 (11%)
diarrhoea 4 (9%)
grade 1-2 3 (7%)
grade 3 1 (2%)
Haematological
WBC 7 (16%)
grade 1-2 7 (16%)
grade 3 0
PLT 0
Hb 2 (4%)
grade 1-2 2 (4%)
Neurological 11 (27%)
grade 1 4 (12%)
grade 2 7 (17%)
Cutaneous pigmentation 2 (6%)
Alopecia none
Cadiac none
Renal none
Therapy-related death none
Discussion
Tegafur (TG) is an anti-metabolite closely related to 5-
fluorouracil (5-FU) and 5-fluorodeoxyuridine (5-FUDR).
Clinical studies have demonstrated that TG exert an
antineoplastic activity comparable to that of 5-FU against
several tumours, including gastrointestinal and breast car-
cinomas (Buroker et al., 1977; Friedman & Ignoffo, 1980;
Schutt et al., 1983). Full dose infusion of TG is often
associated with severe gastrointestinal and neurological tox-
icity, which makes the drug unsuitable for repeated intra-
venous administration. TG, however, is reliably absorbed by
the gastrointestinal tract and low dose oral therapy for
14-21 consecutive days minimises the toxic effects seen after
infusion (Friedman & Ignoffo, 1980; Hunter & Browder,
1980; Bedikian et al., 1983).
We treated 50 consecutive patients affected by advanced
and/or metastatic gastrointestinal tract cancer (GTC) with
oral TG 1,000 mg m-2 on days 1-14. This regimen was
repeated every 28 days or until toxicity recovered. The treat-
ment was generally well tolerated. Mild neurological and
gastrointestinal toxicities were seen respectively in 25% and
48% of patients. Seventeen per cent of 42 evaluable patients
achieved a partial response, 7% had a minor response, 21%
showed a stabilisation of disease and 55% of patients pro-
gressed. This overall response rate confirms our preliminary
results (Palmeri et al., 1986) and is within the range of
activity reported by other authors for oral TG (Browder et
al., 1979; Stroehlein et al., 1981; Ansfeld et al., 1983; Brenner
et al., 1989). A 17% overall response rate was achieved in 18
patients with colorectal cancer, and a 33% response rate was
obtained in patients with gastric carcinoma. No objective
response was seen in pancreatic, gall bladder and liver car-
cinomas. Although Piccinini et al. (1986) reported a 64%
partial response rate in liver carcinoma, our results suggest
that oral TG is ineffective against carcinomas of the
hepatobiliary tract and the pancreas, while it is effective in
gastric and colorectal carcinomas. Since all PRs were
obtained in patients with secondary hepatic neoplastic
lesions, oral TG seems to be particularly effective against
hepatic metastasis.
Three (30%) out of 10 patients previously treated with
5-FU-containing regimens also responded to oral TG, sug-
gesting a possible lack of cross-resistance of TG and 5-FU.
This observation is consistent with the results of Ansfield et
al. (1980), reporting an objective response in 50% of patients
pretreated with 5-FU and progressed thereafter. However,
these data are not confirmed by experimental studies which
demonstrated cross-resistance of TG and 5-FU in mice bear-
ing L1210 lymphocytic leukaemia (Garibjarian et al., 1976).
Initial pharmacological studies showed that TG is a pro-drug
of 5-FU for it is slowly metabolised in the liver by micro-
somal enzymes to 5-FU (Belitsky et al., 1981). 5-FU is in
turn slowly released into the systemic circulation where it
reaches detectable levels for a prolonged period of time
(Garibjanian et al., 1976; Benvenuto et al., 1978; Schilcher et
al., 1983). However, other reports have demonstrated that
5-FU plasma concentrations after TG administration are
almost undetectable and considerably below those observed
after an equivalent intravenous dose of 5-FU (Au & Sadee,
1979; Au et al., 1979; Hornbeck et al., 1981). It seems likely
that TG is intracellularly converted to 5-FU which is further
metabolised before redistribution. As reported by Au et al.
(1979), alternative routes of intracellular activation of TG to
5-FU with the production of active metabolites cannot be
excluded at present. Moreover intracellularly formed 5-FU
may be further metabolised without being redistributed
through the circulation (Au et al., 1979).
Statistical analysis failed to show any significant difference
in survival between patients who enjoyed PR and those who
had a stabilisation. On the other hand, patients who had PR
survived longer than those who progressed (P <0.001).
In conclusion our data suggest that oral therapy with TG
is an active treatment for advanced and/or metastatic gastric
and colorectal carcinomas with mild gastrointestinal and
neurological toxicity, but without a striking positive impact
on survival. No activity was seen in cancers arising from
hepatobiliary system and pancreas. Although data concern-
ing the lack ofcross-resistance between 5-FU and TG are not
conclusive, we feel that oral TG, alone or in combination
with other drugs, may represent a useful drug in the pal-
liative treatment of gastric and colorectal carcinomas. The
employment of TG in cases pretreated with 5-FU is still a
matter of debate.
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